Lymphome

1. Diffuse Large B-Cell Lymphoma. PubMed
2. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. PubMed
3. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. PubMed
4. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and .... PubMed
5. Evolving molecular classification of aggressive B-cell lymphoma. PubMed
6. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. PubMed
7. Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
8. Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
9. Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
10. Zhou X et al. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The oncologist. 2008. PubMed
11. Li B et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2006. PubMed
12. Xia Y et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of immunology (Baltimore, Md. : 1950). 1999. PubMed
13. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
14. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
15. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
16. Adachi Y et al. Potentiation of Antitumor Activity by Antibody Drugs and Mushroom-Derived β-Glucans in Natural Killer Cell-Mediated Tumoricidal Activities against Non-Hodgkin's B-Cell Lymphoma. International journal of medicinal mushrooms. 2023. PubMed
17. Sam J et al. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025. PubMed
18. Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015. PubMed
19. Azoulay T et al. Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression. Cancer immunology, immunotherapy : CII. 2023. PubMed
20. Sato A et al. [Pathogenesis and novel therapy for EBV-related B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2016. PubMed
21. Chen J et al. Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas. Discover oncology. 2025. PubMed
22. Liquidano-Perez E et al. Case Report: Hydroa vacciniforme-like lymphoproliferative disorder, an EBV-associated disease, successfully treated with hematopoietic stem cell transplantation. Frontiers in immunology. 2025. PubMed
23. Song JY et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. Haematologica. 2023. PubMed
24. Greenbaum AM et al. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling. Blood research. 2022. PubMed
25. Liu WR et al. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017. PubMed
26. Wang D et al. Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4. Laboratory investigation; a journal of technical methods and pathology. 2018. PubMed
27. Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology. 2013. PubMed
28. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
29. Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
30. Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
31. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
32. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
33. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
34. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
35. van der Meer JW et al. Trained immunity: A smart way to enhance innate immune defence. Molecular immunology. 2015. PubMed
36. Vuscan P et al. Potent induction of trained immunity by Saccharomyces cerevisiae β-glucans. Frontiers in immunology. 2024. PubMed
37. Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed
38. Liu F et al. The mechanisms for the radioprotective effect of beta-d-glucan on high linear-energy-transfer carbon ion irradiated mice. International journal of biological macromolecules. 2019. PubMed
39. Christophersen OA Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure. Microbial ecology in health and disease. 2012. PubMed
40. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
41. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
42. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed

Afficher toutes les références (42)